The Study
Effect of Bimagrumab on body composition: a systematic review and meta-analysis
This study looked at many small experiments where people were randomly given either bimagrumab or a fake pill, and then measured their muscle and fat. It found that the real medicine made people gain muscle and lose fat—but it didn’t make them stronger or better at walking. So we know it changes body parts, but not how well you can move.
Analysis score
Maximum 100 for a systematic review with meta-analysis.
Where the score came from
This drug helps people with muscle loss gain more muscle and lose fat, but doesn't help them walk faster or get stronger — unless they were already very weak.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 560 / 100
Quality score
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Gaining muscle and losing fat is good, but if you can't walk faster or climb stairs easier, the real-life benefit is limited — unless you were barely able to walk to begin with.
- 2Muscle volume up 5.29%, fat-free mass up 1.90 kg, fat mass down 4.55 kg; walking speed improved by 0.15 m/s only in those who walked slower than 0.8 m/s before.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Aging Clinical and Experimental Research
Year
2024
Authors
Mehmet Kanbay, D. Siriopol, Sidar Copur, N. Hasbal, Mustafa Güldan, K. Kalantar-Zadeh, T. Garfias-Veitl, Stephan von Haehling
Related Content
Claims (6)
Bimagrumab changes body composition in the same way for people with sarcopenia, whether they are older, obese, or have type 2 diabetes, and regardless of the dose they receive between 3 and 700 mg.
In adults with sarcopenia, bimagrumab increases thigh muscle volume by about 5.29%, adds 1.90 kg of fat-free mass, and reduces fat mass by 4.55 kg on average, based on combined results from seven randomized trials lasting 12 to 48 weeks.
In adults with sarcopenia, bimagrumab increases muscle mass but does not lead to measurable improvements in muscle strength, walking speed, or the distance walked in six minutes.
In older adults with severe mobility impairment due to muscle loss, bimagrumab treatment is linked to a measurable increase in walking speed and distance during a six-minute walk test.
Bimagrumab reduces body fat by about 4.55 kilograms in adults with muscle loss due to aging, and this effect is stronger in people who have obesity or insulin resistance.
Bimagrumab blocks specific proteins called activin A and GDF8 that control the growth and maintenance of muscle and fat tissue.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.